Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01236833
Other study ID # 09-225-PED
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received November 8, 2010
Last updated August 2, 2011
Start date November 2010
Est. completion date September 2012

Study information

Verified date August 2011
Source McGill University Health Center
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

The objective of this study is determining if enteral administration of Lactated Ringer's solution (LR) in preterm infants with feeding intolerance enables for faster advancement of milk feeding than fasting.


Description:

Feeding intolerance is a common problem in premature infants in the Neonatal Intensive Care Unit. Definition is clinical and based on abdominal distension, abdominal tenderness, emesis, change in gastric residuals, presence of blood in stool, and apnea with bradycardia.

Feeding intolerance is associated with serious complications: necrotizing enterocolitis, longer hospitalization and prolonged intravenous nutrition complications (e.g. sepsis, liver damage). Therefore, the investigators aim to achieve adequate enteral nutrition as soon as possible.

Because LR is a an amniotic fluid-like solution, it may improve gastro-intestinal function and avoid fasting, as well as its multiple problems (e.g. intestinal atrophy and decreased intestinal motility). LR was chosen as the test solution because of experience documenting its safe use in comparable groups: in newborn resuscitation parenterally, in amnioinfusion, and in bowel irrigation. Moreover, LR is similar in electrolytes composition to the experimental solution used in previous studies by Barney et al in neonates.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date September 2012
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Birth gestational age (GA) between 25 and 32 weeks

- Corrected gestational age less than 34 weeks

- Enteral feeding tolerated at a minimum of 10 ml/kg/day for a minimum of 48 hours

- Severe feeding intolerance, defined as a minimum of one or more of the following signs leading to withholding of milk feedings on two evaluations over 12 to 24 hours:

1. Significant increased abdominal girth, as evaluated by the treatment team, with abdominal tenderness

2. Visible enlarged bowel loops with abdominal tenderness

3. Recurrent emesis leading to withhold feeds

4. Gastric residuals in excess of one feeding, recurrent or with growing abdominal girth

5. Visible blood in stools without anal etiology

- Documented informed consent for participation in the study

Exclusion Criteria:

- Infants who already reached full enteral feeds for 72 hours, in fact a minimum of 130 ml/kg/day enteral feeds without parenteral supplementation.

- Small for gestational age (SGA) (weight at or less than the 3rd percentile on the Fenton growth chart)

- NEC (Bell's stage II or higher, radiologic evidence of NEC, pneumatosis intestinalis or free intraperitoneal air)or history of NEC

- Gastric or intestinal occlusion (no transit, absent bowel sounds, incessant vomiting, bile stained vomiting or air fluid levels)

- Major congenital malformation

- Septic infants requiring therapeutic antibiotics or antimycotics (infants only on prophylactic antibiotics or antimycotics should not be excluded).

- Patients judged as being too ill to enroll in this study, as defined by a requirement for mechanical ventilation with >50% FIO2

- Patent Ductus Arteriosus requiring ibuprofen, indomethacin or ligature, until one week after the end of treatment

- Intraventricular Haemorrhage grade 3 or 4

- Hypernatremia = 150 mmol/L

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Lactated Ringer's Solution
2.5 ml per kg every 3 hours, via nasogastric tube, orogastric tube or orally, until the infant reaches 80 ml/kg/day of milk feeding or for a maximum of 14 days

Locations

Country Name City State
Canada Jewish General Hospital Montreal Quebec
Canada McGill University Health Center Montreal Quebec

Sponsors (1)

Lead Sponsor Collaborator
McGill University Health Center

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Barney CK, Lambert DK, Alder SC, Scoffield SH, Schmutz N, Christensen RD. Treating feeding intolerance with an enteral solution patterned after human amniotic fluid: a randomized, controlled, masked trial. J Perinatol. 2007 Jan;27(1):28-31. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Average of the daily enteral caloric intake (in calories/kg/day) received over the 14 days after study entry To measure enteral caloric intake, the volume of milk feeding, for each patient will be recorded daily and for 14 days. Unfortified milk and fortified milk are calculated as containing respectively 0.67 Cal/ml and 0.81 Cal/ml. 14 days No
Secondary Number of days to reach 130 ml/kg milk feeding variable No
Secondary Number of days to discontinue IV access variable Yes
Secondary Growth (weight, height, head circumference), increase % after 14 days and between study entry and discharge home variable No
Secondary Length of hospitalization variable No
Secondary Necrotizing enterocolitis during the 14 day-study period and hospitalization Yes
Secondary Electrolytes, bilirubin, serum urea nitrogen, creatinine and liver enzymes 14 days Yes
Secondary Infections until discharge Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT05194527 - The Detrimental Course of Acute Intestinal Ischemia
Recruiting NCT04605627 - The Role of Gut Leakage Markers and Microbiota Signature in Coronary Artery Disease.
Enrolling by invitation NCT04502784 - Investigation of Hypophosphataemia Following Intravenous Iron
Completed NCT03559543 - Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Phase 2
Completed NCT03723447 - Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®) Phase 4
Completed NCT04573959 - Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System N/A
Not yet recruiting NCT04123990 - Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel Disease N/A
Not yet recruiting NCT06271538 - Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome Phase 4
Completed NCT02785783 - Endorings™ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection N/A
Completed NCT03012594 - Lanreotide in the Treatment of Small Bowel Motility Disorders Phase 2
Recruiting NCT06007313 - Mental Stress and Bowel Preparation Quality
Completed NCT04982302 - Gut Microbial Changes After Periodontal Treatment
Completed NCT03543540 - Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease Phase 1
Completed NCT03817645 - Panaceo "MED" for IBS (Irritable Bowel Syndrome) N/A
Completed NCT00072943 - A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease Phase 2
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03280407 - NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer Phase 2
Completed NCT04263818 - Endoscopist and Endoscope Motions During Colonoscopy N/A
Recruiting NCT05923918 - A Study to Evaluate Safety and Efficacy of PBK_M2101 Phase 3